Randomized trials are warranted to evaluate if treating HHV-6B reactivation improves outcomes.
Large study from China identifies adverse outcomes associated with, and risk factors for, HHV-6 encephalitis in post-HSCT patients
Greatly increased risk of death, acute GVHD, transplant-associated microangiopathy found.
After screening 100,000 compounds, Merck identified a potent broad-spectrum herpesvirus antiviral
The new small molecule non-nucleoside inhibitor was effective in both in vitro and in vivo studies although no testing against HHV-6 was reported.
Although 28% of children undergoing chemotherapy develop herpesvirus viremia, there is minimal clinical impact
HHV-6, CMV and HSV1/2 were the most likely to reactivate, but herpesvirus reactivation was just as likely prior to chemotherapy.
Lower levels of torque teno virus correlate with higher HHV-6A viral loads and higher rejection rates in kidney transplantation
Value of this observation in determining prognosis or guiding treatment remains to be studied.
How frequent are HHV-6-related complications with CAR-T cell therapy?
A combination of studies find that both reactivation and disease are infrequent after CAR-T therapy.
Febrile status epilepticus in infants with MRI-confirmed brain abnormalities linked to temporal lobe epilepsy later in life
Surprisingly, although HHV-6B has been linked to febrile seizures, febrile status epilepticus and temporal lobe epilepsy, the report contains no mention of the virus.
HHV-6 & acute pediatric hepatitis of unknown cause: Japan’s experience
Adeno-associated virus (AAV) linked to Japanese cases, but whether HHV-6 was a cofactor is uncertain.
HHV-6 found to be possible etiologic agent in some cases of acute hepatitis of unknown origin
Israeli study of 20 pediatric cases occurring in 2021 found more evidence for HHV-6 than for other viruses, including AAV2 and SARS-CoV-2.
Centrilobular necroinflammation associated with pediatric HHV-6+ acute liver failure
Would early treatment with antiviral therapy prevent the need for a liver transplant?
Co-infection of HHV-6A and EBV results in a 6.7 fold increased risk of developing multiple sclerosis
The increased risk occurred only in adults who were infected with EBV after their teenage years, and had elevated EBNA-1 antibodies.
Why does substituting CMV-specific letermovir for broad-spectrum anti-viral prophylaxis reduce the rate of HHV-6B encephalitis?
Japanese study replicates the paradoxical results of a prior US study, but fails to explain the paradox.
Antibodies to HHV-6 and HHV-6 dUTPase are strong predictors of Long COVID
CRP and IgA antibodies to activin-A are also important predictors.
New mechanism identified by which HHV-6B evades NK cell recognition
HHV-6B U20 protein inhibits NK cell attacks on virally-infected cells.
MicroRNA expression patterns suggest that HHV-6 may play a role in triggering systemic sclerosis
Expression pattern of several miRNAs in SS tissue parallels the pattern generated when dermal fibroblasts and endothelial cells are infected by HHV-6A and CMV.